Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q1 EPS of ($0.09), $0.04 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $105.4 million versus the consensus estimate of $103.72 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.